$Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells$

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells

Combination effects of docetaxel (DOC) and doxorubicin (DOX) were investigated in prostate cancer cells (PC3 and DU145). Combination indices (CIs) were determined using the unified theory in various concentrations and mixing ratios (synergy: CI<0.9, additivity: 0.9<CI<1.1, and antagonism: C...

Full description

Saved in:

Bibliographic Details
Main Authors:	Eleftheria Tsakalozou, Allison M. Eckman, Younsoo Bae
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	Biochemistry Research International
Online Access:	http://dx.doi.org/10.1155/2012/832059
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
by: Bin Han, et al.
Published: (2012-01-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

ABA enhances the apoptotic effect of docetaxel in the multidrug-resistant DU145 prostate cancer cell line
by: Şumnulu Deniz, et al.
Published: (2024-01-01)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01)

De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review
by: Hanxu Guo, et al.
Published: (2025-01-01)

Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
by: Osama Diab, et al.
Published: (2019-01-01)

Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Seiichi Kato, et al.
Published: (2021-01-01)

A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
by: Aseem Samar, et al.
Published: (2020-01-01)

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis
by: Ying Zhang, et al.
Published: (2025-01-01)

AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer
by: Hong Wang, et al.
Published: (2025-01-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells
by: Sima Kianpour Rad, et al.
Published: (2025-01-01)

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
by: Furnback W, et al.
Published: (2025-02-01)

Circadian Rhythms and Breast Cancer: The Role of Per2 in Doxorubicin-Induced Cell Death
by: Megan I. Mitchell, et al.
Published: (2015-01-01)

Effectiveness of GnRH Antagonists and Agonists in Patients with Hormone-Sensitive Prostate Cancer: A Retrospective Study
by: Zhenghao Liu, et al.
Published: (2022-01-01)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
by: Hamid Reza Mirzaei, et al.
Published: (2013-01-01)

Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma
by: Ming-Chun Ma, et al.
Published: (2014-01-01)

Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer
by: Feng Qi, et al.
Published: (2025-01-01)

IFN-γ reprograms cardiac microvascular endothelial cells to mediate doxorubicin transport and influences the sensitivity of mice to doxorubicin-induced cardiotoxicity
by: Haoyu Ji, et al.
Published: (2025-01-01)

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
by: Joo Young Jung, et al.
Published: (2016-01-01)

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Comparative analysis of combined methylene blue photodynamic therapy and doxorubicin treatment of oral squamous cell carcinoma cell line: In vitro study on apoptosis
by: Shayan Momeni Goujani, et al.
Published: (2025-02-01)

Effect of Coenzyme-Q10 on Doxorubicin-Induced Nephrotoxicity in Rats
by: Azza A. K. El-Sheikh, et al.
Published: (2012-01-01)

Possible Protective Effect of Diacerein on Doxorubicin-Induced Nephrotoxicity in Rats
by: Marwa M. M. Refaie, et al.
Published: (2016-01-01)

Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro
by: Rudolfová Petra, et al.
Published: (2014-06-01)

Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer
by: Lei Wang, et al.
Published: (2022-01-01)

Interleukin 15‐Presenting Nanovesicles with Doxorubicin‐Loaded Ferritin Cores for Cancer Immunochemotherapy
by: Yihui Zhai, et al.
Published: (2025-01-01)

Enhanced Expression of ABCB1 and Nrf2 in CD133-Positive Cancer Stem Cells Associates with Doxorubicin Resistance
by: Shinji Goto, et al.
Published: (2020-01-01)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
by: Ninna Aggerholm-Pedersen, et al.
Published: (2016-01-01)

Exercise training partly ameliorates cardiac dysfunction in mice during doxorubicin treatment of breast cancer
by: Tytti-Maria Uurasmaa, et al.
Published: (2025-01-01)

Determination of protective effectiveness of nerium oleander distillation in doxorubicin-induced organ damages
by: Burak Dik, et al.

Effective Treatment of a Malignant Breast Phyllodes Tumor with Doxorubicin-Ifosfamide Therapy
by: Shinya Yamamoto, et al.
Published: (2019-01-01)

Prostate Cancer
by: Scott Eggener
Published: (2011-01-01)

Hydrazinyldiene-chroman-2,4-diones in inducing growth arrest and apoptosis in breast cancer cells: Synergism with doxorubicin and correlation with physicochemical properties
by: Ballazhi Lulzime, et al.
Published: (2017-03-01)

Apelinergic System Affects Electrocardiographic Abnormalities Induced by Doxorubicin
by: Kasper Buczma, et al.
Published: (2025-01-01)

A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
by: Danilo Giffoni de Mello Morais Mata, et al.
Published: (2024-12-01)

The Anti-proliferative Effect of a Novel Glutaminase Inhibitor IN-3 on Prostate Cancer Cells
by: Ummuhan DEMIR, et al.
Published: (2024-09-01)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
by: Kuang Youlin, et al.
Published: (2012-01-01)

Editorial: Prostate cancer research: tools, cancer cell types, molecular targets
by: Hung-Ming Lam, et al.
Published: (2025-02-01)